Literature DB >> 18759361

Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia.

Roy C Martin1, Ozioma C Okonkwo, Joni Hill, H Randall Griffith, Kristen Triebel, Alfred Bartolucci, Anthony P Nicholas, Ray L Watts, Natividad Stover, Lindy E Harrell, David Clark, Daniel C Marson.   

Abstract

Little is currently known about the higher order functional skills of patients with Parkinson disease and cognitive impairment. Medical decision-making capacity (MDC) was assessed in patients with Parkinson's disease (PD) with cognitive impairment and dementia. Participants were 16 patients with PD and cognitive impairment without dementia (PD-CIND), 16 patients with PD dementia (PDD), and 22 healthy older adults. All participants were administered the Capacity to Consent to Treatment Instrument (CCTI), a standardized capacity instrument assessing MDC under five different consent standards. Parametric and nonparametric statistical analyses were utilized to examine capacity performance on the consent standards. In addition, capacity outcomes (capable, marginally capable, or incapable outcomes) on the standards were identified for the two patient groups. Relative to controls, PD-CIND patients demonstrated significant impairment on the understanding treatment consent standard, clinically the most stringent CCTI standard. Relative to controls and PD-CIND patients, PDD patients were impaired on the three clinical standards of understanding, reasoning, and appreciation. The findings suggest that impairment in decisional capacity is already present in cognitively impaired patients with PD without dementia and increases as these patients develop dementia. Clinicians and researchers should carefully assess decisional capacity in all patients with PD with cognitive impairment. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18759361      PMCID: PMC2579319          DOI: 10.1002/mds.22170

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

1.  Bedside assessment of executive cognitive impairment: the executive interview.

Authors:  D R Royall; R K Mahurin; K F Gray
Journal:  J Am Geriatr Soc       Date:  1992-12       Impact factor: 5.562

2.  Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

Authors:  Carmen Cristea Janvin; Jan Petter Larsen; Dag Aarsland; Kenneth Hugdahl
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

3.  Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease.

Authors:  M N Sabbagh; T Lahti; D J Connor; J N Caviness; H Shill; L Vedders; P Mahant; J Samanta; R S Burns; V G H Evidente; E Driver-Dunckley; B Reisberg; S Bircea; C H Adler
Journal:  Dement Geriatr Cogn Disord       Date:  2007-09-13       Impact factor: 2.959

4.  Parkinson's disease and driving ability.

Authors:  Rajiv Singh; Brian Pentland; John Hunter; Frances Provan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

5.  Medical decision-making in neurodegenerative disease: mild AD and PD with cognitive impairment.

Authors:  H R Griffith; M P Dymek; P Atchison; L Harrell; D C Marson
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

6.  Assessing the competency of patients with Alzheimer's disease under different legal standards. A prototype instrument.

Authors:  D C Marson; K K Ingram; H A Cody; L E Harrell
Journal:  Arch Neurol       Date:  1995-10

7.  Medical decision-making capacity in patients with mild cognitive impairment.

Authors:  O Okonkwo; H R Griffith; K Belue; S Lanza; E Y Zamrini; L E Harrell; J C Brockington; D Clark; R Raman; D C Marson
Journal:  Neurology       Date:  2007-10-09       Impact factor: 9.910

8.  Assessing patients' capacities to consent to treatment.

Authors:  P S Appelbaum; T Grisso
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

9.  Defining mild cognitive impairment in Parkinson's disease.

Authors:  John N Caviness; Erika Driver-Dunckley; Donald J Connor; Marwan N Sabbagh; Joseph G Hentz; Brie Noble; Virgilio Gerald H Evidente; Holly A Shill; Charles H Adler
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more
  23 in total

1.  Utility of the NeuroTrax computerized battery for cognitive screening in Parkinson's disease: comparison with the MMSE and the MoCA.

Authors:  B Hanna-Pladdy; A Enslein; M Fray; B J Gajewski; R Pahwa; K E Lyons
Journal:  Int J Neurosci       Date:  2010-08       Impact factor: 2.292

Review 2.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

Review 3.  Cognition in movement disorders: where can we hope to be in ten years?

Authors:  David Burn; Daniel Weintraub; Bernard Ravina; Irene Litvan
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 4.  Assessment of Healthcare Decision-making Capacity.

Authors:  Barton W Palmer; Alexandrea L Harmell
Journal:  Arch Clin Neuropsychol       Date:  2016-08-22       Impact factor: 2.813

5.  Research consent capacity varies with executive function and memory in Parkinson's disease.

Authors:  Stephen T Moelter; Daniel Weintraub; Lauren Mace; Mark Cary; Elizabeth Sullo; Sharon X Xie; Jason Karlawish
Journal:  Mov Disord       Date:  2016-02-10       Impact factor: 10.338

6.  Neurocognitive Models of Medical Decision-Making Capacity in Traumatic Brain Injury Across Injury Severity.

Authors:  Kristen L Triebel; Thomas A Novack; Richard Kennedy; Roy C Martin; Laura E Dreer; Rema Raman; Daniel C Marson
Journal:  J Head Trauma Rehabil       Date:  2016 May-Jun       Impact factor: 2.710

7.  Medical decision-making capacity in patients with malignant glioma.

Authors:  Kristen L Triebel; Roy C Martin; Louis B Nabors; Daniel C Marson
Journal:  Neurology       Date:  2009-12-15       Impact factor: 9.910

8.  Assessment of functional change and cognitive correlates in the progression from healthy cognitive aging to dementia.

Authors:  Maureen Schmitter-Edgecombe; Carolyn M Parsey
Journal:  Neuropsychology       Date:  2014-06-16       Impact factor: 3.295

9.  Enhancing Medical Decision-Making Evaluations: Introduction of Normative Data for the Capacity to Consent to Treatment Instrument.

Authors:  Adam Gerstenecker; Lindsay Niccolai; Daniel Marson; Kristen L Triebel
Journal:  Assessment       Date:  2015-08-17

10.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.